DEA Pushes for CAMU-Based Reclassification of Cannabis at Rescheduling Hearing
TL;DR
At a two-week administrative hearing, the DEA urged that cannabis be moved from Schedule I toward Schedule III by showing it has currently accepted medical use (CAMU) based on FDA/HHS analysis and clinical data; anti-rescheduling groups contested the CAMU framework and the traditional five-factor test. The proceedings feature FDA scientist Dominic Chiapperino and cross-examinations, with the outcome expected to emerge later in the process.
Topics:nationregulations-and-reform#camu#dea-cannabis-rescheduling-hearing#fda#hhs#regulations-and-reform#schedule-iii
- DEA Comes Out Swinging in Cannabis Rescheduling Hearing Cannabis Business Times
- DEA And FDA Highlight How Marijuana Is Safer Than Alcohol And Opioids During Rescheduling Hearing's Opening Day Marijuana Moment
- Rescheduling marijuana would put politics ahead of science The Hill
- DEA Kicks Off Historic Hearing On Cannabis Rescheduling Proposal Forbes
- What to expect from the DEA marijuana rescheduling hearing MJBizDaily
Want the full story? Read the original reporting
Read on Cannabis Business Times